Oppenheimer Cuts BioMarin Pharmaceutical Price Target

Wall Street firm reduces outlook for biotech company's stock price

Feb. 27, 2026 at 6:40am

Got story updates? Submit your updates here. ›

Oppenheimer, an investment research firm, has lowered its price target for BioMarin Pharmaceutical (NASDAQ:BMRN) from $98.00 to $95.00 per share. The firm maintains an 'outperform' rating on the biotechnology company's stock. Other analysts have also issued mixed ratings and price targets for BioMarin in recent months.

Why it matters

BioMarin Pharmaceutical is a leading biopharmaceutical company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Analyst price target adjustments can impact investor sentiment and trading activity around the company's stock.

The details

In a research note published on Tuesday, Oppenheimer cited ongoing business and pipeline developments at BioMarin as the rationale for reducing its price target, though the firm remains optimistic about the company's long-term prospects. Other analysts have also weighed in on BioMarin recently, with Canaccord Genuity upgrading the stock to 'buy' and raising its price target, while Wall Street Zen downgraded the shares to 'hold'.

  • Oppenheimer published its updated research note on BioMarin on Tuesday, February 27, 2026.

The players

Oppenheimer

An investment research firm that covers BioMarin Pharmaceutical and has adjusted its price target for the company's stock.

BioMarin Pharmaceutical

A biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

Analyst price target adjustments can influence investor sentiment around a company's stock, though BioMarin's long-term prospects remain promising as it continues to advance its pipeline of rare disease therapies.